Yes, that’s true but significantly increasing the oral dose (x7) could theoretically provide an equivalent systemic effect while staying under the AE threshold (eg macular problems). It would be actually quite interesting to know the prevalence of OA in long term users of Elmiron for cystitis.
As we know, when taken for cystitis the drug works not as a systemic treatment but rather the opposite - it goes straight to the bladder where it hangs around long enough to reduce inflammation, before being excreted through the normal channels.
It might be possible at some point to tweak the Elmiron formula to provide greater bioavailability when taken orally, especially given the size of the potential market.
- Forums
- ASX - By Stock
- PAR
- General OA media and info
General OA media and info, page-122
-
- There are more pages in this discussion • 549 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 280011 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 44703 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 280011 | 0.230 |
9 | 131672 | 0.225 |
11 | 91449 | 0.220 |
2 | 38958 | 0.215 |
5 | 81017 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 44703 | 3 |
0.245 | 84375 | 3 |
0.250 | 33573 | 2 |
0.255 | 29564 | 3 |
0.260 | 33915 | 5 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |